'Stuffed': users of supplementary patented components in drug combos can be sued - European court
This article was originally published in Scrip
Executive Summary
A recent decision from the Court of Justice of the European Union has shed more light on the messy regulations governing supplementary protection certificates (which give five years extra IP protection) and the use of certificated-protected components in combination products.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.